AR121016A2 - Sales de fenotiazindiaminio y su uso - Google Patents

Sales de fenotiazindiaminio y su uso

Info

Publication number
AR121016A2
AR121016A2 ARP210100056A ARP210100056A AR121016A2 AR 121016 A2 AR121016 A2 AR 121016A2 AR P210100056 A ARP210100056 A AR P210100056A AR P210100056 A ARP210100056 A AR P210100056A AR 121016 A2 AR121016 A2 AR 121016A2
Authority
AR
Argentina
Prior art keywords
4alkyl
independently selected
4alkenyl
halogenated
salts
Prior art date
Application number
ARP210100056A
Other languages
English (en)
Inventor
Janet Elizabeth Rickard
James Peter Sinclair
Michael Simpson
John Mervyn David Storey
Thomas Craven Baddeley
Karrar Ahmad Khan
Barry Alan Wood
Craig Williamson
Scott Clunas
Charles Robert Harrington
Yin Sze Loh
Colin Marshall
Ahtsham Ishaq
David Horsley
Claude Michel Wischik
Christopher Paul Larch
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of AR121016A2 publication Critical patent/AR121016A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/20[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029Radiation
    • A61L2/0052Visible light
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35Naphthalene sulfonic acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de fórmula general (1) donde: cada uno de R¹ y R⁹ se selecciona en forma independiente entre: -H, C₁₋₄alquilo, C₂₋₄alquenilo, y C₁₋₄alquilo halogenado; cada uno de R³NA y R³NB se selecciona en forma independiente entre: -H, C₁₋₄alquilo, C₂₋₄alquenilo, y C₁₋₄alquilo halogenado; cada uno de R⁷NA y R⁷NB se selecciona en forma independiente entre: -H, C₁₋₄alquilo, C₂₋₄alquenilo, y C₁₋₄alquilo halogenado; y donde: cada uno de RA y RB se selecciona en forma independiente entre: C₁₋₄alquilo, C₁₋₄alquilo halogenado, y C₆₋₁₀arilo; o RA y RB se unen para formar un grupo seleccionado entre: C₁₋₆ alquileno y C₆₋₁₀ arileno; y sales farmacéuticamente aceptables del mismo, que son de utilidad en el tratamiento, por ejemplo, de la enfermedad de Alzheimer. Formulaciones de sales de 3,7-diamino-10H-fenotiazinio. Reivindicación 1: Un compuesto caracterizado porque se selecciona entre: el compuesto de fórmula (2) o una sal farmacéuticamente aceptable, solvato, o hidrato del mismo.
ARP210100056A 2011-02-11 2021-01-11 Sales de fenotiazindiaminio y su uso AR121016A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG2011010600 2011-02-11

Publications (1)

Publication Number Publication Date
AR121016A2 true AR121016A2 (es) 2022-04-06

Family

ID=44532939

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110102969A AR082699A1 (es) 2011-02-11 2011-08-16 Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto
ARP210100056A AR121016A2 (es) 2011-02-11 2021-01-11 Sales de fenotiazindiaminio y su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110102969A AR082699A1 (es) 2011-02-11 2011-08-16 Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto

Country Status (26)

Country Link
US (5) US9283230B2 (es)
EP (1) EP2673266B1 (es)
JP (2) JP5898701B2 (es)
KR (1) KR101888713B1 (es)
CN (2) CN103649061B (es)
AR (2) AR082699A1 (es)
AU (1) AU2011358840B2 (es)
BR (1) BR112013020539A2 (es)
CA (1) CA2827027C (es)
CY (1) CY1118102T1 (es)
DK (1) DK2673266T3 (es)
EA (1) EA025033B1 (es)
ES (1) ES2594703T3 (es)
HK (1) HK1186738A1 (es)
HR (1) HRP20161291T1 (es)
HU (1) HUE031633T2 (es)
IL (2) IL227736A (es)
LT (1) LT2673266T (es)
MY (1) MY165906A (es)
PL (1) PL2673266T3 (es)
PT (1) PT2673266T (es)
RS (1) RS55237B1 (es)
SG (1) SG192666A1 (es)
SI (1) SI2673266T1 (es)
SM (1) SMT201600389B (es)
WO (1) WO2012107706A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2013191T6 (pl) 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
LT2457905T (lt) 2006-07-11 2016-11-10 Wista Laboratories Ltd. Diaminofenotiazino junginių sintezės ir (arba) gryninimo metodai
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
CN103649061B (zh) 2011-02-11 2016-04-20 维斯塔实验室有限公司 吩噻嗪二胺鎓盐和其用途
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2015021500A1 (en) * 2013-08-15 2015-02-19 Eupharma Pty Ltd Process for the purification of diaminophenothiazinium compounds
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
WO2015171592A1 (en) * 2014-05-06 2015-11-12 Milliken & Company Laundry care compositions
KR20170137101A (ko) * 2015-04-16 2017-12-12 노파르티스 아게 리보시클립 정제
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3,7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
CN106046027B (zh) * 2016-06-30 2019-03-05 广东工业大学 一种含吡咯并吩噻嗪-1,3-二酮衍生物及其制备方法与应用
WO2018019823A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
JP6958860B2 (ja) 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
KR20240132122A (ko) 2018-09-05 2024-09-02 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 신경퇴행성 질환에 대한 네트워크 방법
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN115916211A (zh) * 2020-05-05 2023-04-04 维斯塔实验室有限公司 用于治疗低氧血症的甲基硫堇鎓化合物
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
US20230165875A1 (en) 2020-05-05 2023-06-01 Wista Laboratories Ltd. Methylthioninium compounds for use in the treatment of covid-19
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
KR102396975B1 (ko) 2022-01-11 2022-05-12 이덕형 페이스 리프팅기 및 이를 위한 동작 방법
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023202464A1 (zh) * 2022-04-19 2023-10-26 英科隆生物技术(杭州)有限公司 一种电子媒介体的提纯方法
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
WO2024115630A1 (en) * 2022-11-30 2024-06-06 CERNY, Erich Methylene blue for use in therapy of hepatitis b and/or hepatitis d infection
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (es) 1957-07-17
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エー.ヴェー. アルツハイマー病の診断および治療用の新規な手段
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
EP0778773A1 (en) 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
JP2001514617A (ja) 1997-01-21 2001-09-11 ジ・アメリカン・ナショナル・レッド・クロス 両親媒性フェノチアジン−5−イウム染料と光による全血および血液成分の細胞内および細胞外汚染除去
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
EP1248518A2 (en) 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
BRPI0416928A (pt) 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
PL2322517T3 (pl) 2004-09-23 2019-09-30 Wista Laboratories Ltd. Sposoby syntezy chemicznej i oczyszczania związków diaminofenotiazyniowych, w tym chlorku metylotioniny (MTC)
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
US20070116757A1 (en) 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
PL2013191T6 (pl) * 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
SI2853293T1 (en) 2006-03-29 2018-03-30 Wista Laboratories Ltd. Tioninium compounds and their use
ES2667002T3 (es) 2006-03-29 2018-05-09 Wista Laboratories Ltd. Inhibidores de la agregación de proteínas
LT2457905T (lt) 2006-07-11 2016-11-10 Wista Laboratories Ltd. Diaminofenotiazino junginių sintezės ir (arba) gryninimo metodai
MY177001A (en) 2007-06-19 2020-09-01 Wista Lab Ltd Phenothiazine compounds for treating mild cognitive impairment
US9149481B2 (en) * 2007-10-03 2015-10-06 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
CN103649061B (zh) 2011-02-11 2016-04-20 维斯塔实验室有限公司 吩噻嗪二胺鎓盐和其用途

Also Published As

Publication number Publication date
US20220098161A1 (en) 2022-03-31
IL249056A0 (en) 2017-01-31
US11180464B2 (en) 2021-11-23
EA201391158A8 (ru) 2016-05-31
US9283230B2 (en) 2016-03-15
SG192666A1 (en) 2013-09-30
MY165906A (en) 2018-05-18
WO2012107706A8 (en) 2013-09-19
EP2673266B1 (en) 2016-07-27
ES2594703T3 (es) 2016-12-22
IL227736A (en) 2017-07-31
US12064439B2 (en) 2024-08-20
EP2673266A1 (en) 2013-12-18
US9907804B2 (en) 2018-03-06
SMT201600389B (it) 2017-01-10
IL249056B (en) 2019-09-26
PL2673266T3 (pl) 2017-01-31
PT2673266T (pt) 2016-10-07
JP2014505095A (ja) 2014-02-27
US20190046537A1 (en) 2019-02-14
HK1186738A1 (zh) 2014-03-21
LT2673266T (lt) 2016-10-10
KR20140007428A (ko) 2014-01-17
JP2016138117A (ja) 2016-08-04
DK2673266T3 (en) 2016-10-24
CY1118102T1 (el) 2017-06-28
AU2011358840A1 (en) 2013-09-12
HUE031633T2 (en) 2017-07-28
US10864216B2 (en) 2020-12-15
EA201391158A1 (ru) 2014-02-28
AR082699A1 (es) 2012-12-26
CA2827027C (en) 2019-06-04
WO2012107706A1 (en) 2012-08-16
EA025033B1 (ru) 2016-11-30
RS55237B1 (sr) 2017-02-28
CN103649061B (zh) 2016-04-20
IL227736A0 (en) 2013-09-30
US20130315992A1 (en) 2013-11-28
JP6093890B2 (ja) 2017-03-08
US20160237048A1 (en) 2016-08-18
US20200246350A1 (en) 2020-08-06
AU2011358840B2 (en) 2017-05-04
CN103649061A (zh) 2014-03-19
BR112013020539A2 (pt) 2017-09-26
HRP20161291T1 (hr) 2016-11-18
CA2827027A1 (en) 2012-08-16
CN105853439A (zh) 2016-08-17
JP5898701B2 (ja) 2016-04-13
SI2673266T1 (sl) 2016-11-30
KR101888713B1 (ko) 2018-08-14

Similar Documents

Publication Publication Date Title
AR121016A2 (es) Sales de fenotiazindiaminio y su uso
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
GT201600123A (es) Inhibidores de syk
AR101177A1 (es) Inhibidores de la syk
AR099489A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CR20140413A (es) Inhibidores de serina/treonina cinasa
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
CU20170007A7 (es) Compuestos de imidazopiridazina
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1